Overview
Pharmaceutical

WAKAMOTO PHARMACEUTICAL CO.,LTD.

Wakamoto Pharmaceutical is a Japanese pharmaceutical and healthcare company operating across four segments: Medical (pharmaceuticals including branded and generic drugs, medical devices, and health foods primarily in the ophthalmology field), Healthcare (OTC products including the flagship 'Kyoryoku Wakamoto' digestive supplement, medicated toothpaste 'Avanbees', and femcare products), Global (export of products and pharmaceutical ingredients to Asia and Europe, plus contract manufacturing and diagnostics), and Real Estate (rental income from Coredo Muromachi). The company leverages proprietary fermentation technology using koji, lactic acid bacteria, and yeast as a core scientific competency.

Market Cap
¥10.3B
US$66.0M
EV
¥6.93B
US$44.2M
Stock¥298▼-1.32%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
9.5
x
LTM EV/EBIT
26.4
x
LTM PER
30.3
x
LTM PBR
0.9
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-19.8%pt
10012
Oct 23, 25 – Oct 23, 26StockTOPIX
1Jan 9, 26Asset Value Investors Limited changed stake (9.58%→10.6%)
2Aug 27, 26Asset Value Investors Limited changed stake (10.6%→11.64%)
MC → EV Bridge
10.3BUS$66.0MMarket Cap0.40BUS$2.55M+ Debt1.92BUS$12.2M− Cash1.90BUS$12.1M− Inv. Sec.6.93BUS$44.2MEV
AI Briefing
Wakamoto Pharmaceutical: fermentation-rooted ophthalmology player with legacy OTC brand 'Kyoryoku Wakamoto', plus export and real estate income streams. FY26/3 revenue ¥9.9B, OP ¥0.3B (2.6%) — swing back to profit after two loss-making years. Fragmented register with Rohto and Kissei as strategic holders alongside activist AVI Japan; EV/EBITDA fwd ~10x on thin ¥0.7B EBITDA base, M&A interest plausible given shareholder structure.
Performance & Balance
Revenue 5Y (¥B)
8.38US$53.5M'22/38.66US$55.2M'23/37.74US$49.3M'24/37.79US$49.7M'25/39.91US$63.2M'26/3
EBITDA 5Y (¥B)
0.46US$2.92M'22/30.59US$3.74M'23/30.22US$1.38M'24/3-0.03-US$0.17M'25/30.70US$4.45M'26/3
Net Income 5Y (¥B)
0.24US$1.52M'22/30.14US$0.88M'23/30.11US$0.69M'24/30.06US$0.41M'25/30.23US$1.45M'26/3
Capital Structure
97%
EquityD/E 0.03xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
5.30US$33.8M0.10US$0.65M'22/36.36US$40.6M0.10US$0.65M'23/36.11US$38.9M0.10US$0.64M'24/34.80US$30.6M0.10US$0.64M'25/34.26US$27.2M0.40US$2.55M'26/3
Shareholders
Top 10 hold 58.8%
1
ROHTO PHARMACEUTICAL CO.,LTD.
11.44%
2
KISSEI PHARMACEUTICAL CO.,LTD.
10.89%
3
AVI JAPAN OPPORTUNITY TRUST PLC (Standing Proxy: Mizuho Bank, Ltd.)
8.64%
4
Brest Sieve Co., Ltd.
7.20%
5
WAKAMOTO PHARMACEUTICAL CO.,LTD. Business Partners' Stock Ownership Association
5.80%
6
Asahi Mutual Life Insurance Company
3.47%
7
Nippon Zettoc Co., Ltd.
3.46%
8
Mizuho Bank, Ltd.
3.15%
9
SG/UCITS V/INV (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch, Securities Services Operations)
2.50%
10
AXA Life Insurance Co.,Ltd.
2.28%
Management
8 officers
Tomoyuki HIRAI
Representative Director, President
Apr 1989 Joined The Industrial Bank of Japan, Ltd. (now Mizuho Financial Group, Inc.) Apr 2002 Business Development Group Leader, Kogin Dai-Ichi Life Asset Management, Inc. (now Asset Management OneA Co., Ltd.) Oct 2005 Manager, Securities Research Section, Mizuho Corporate Bank, Ltd. Apr 2009 Professor, Graduate School of Accounting and Finance, Chiba University of Commerce (until Mar 2018) Apr 2010 Deputy General Manager, Asset Management Department, Mizuho Corporate Bank, Ltd. Apr 2016 Managing Director; Head of Public Sector, Financial & Public Sector Division, Mizuho Securities Co., Ltd. Apr 2018 Deputy Head, Financial & Public Sector Division, Mizuho Securities Co., Ltd. Jun 2021 Director, Seibu Oil Co., Ltd. Apr 2023 Joined the Company as Officer Jan 2024 General Manager, Corporate Planning Office; General Manager, General Affairs Department; General Manager, Public Relations Office Jun 2024 Managing Director; General Manager, Administration Division; General Manager, Corporate Planning Office; General Manager, Sustainability Promotion Office Apr 2026 Representative Director, President (current)
1965-10-09
Arata IGARASHI
Director, Chairman of the Board
Apr 1981 Joined The Industrial Bank of Japan, Ltd. (now Mizuho Financial Group, Inc.) Apr 2005 General Manager, Credit Engineering Department, Mizuho Corporate Bank, Ltd. Apr 2008 General Manager, 14th Sales Department, Mizuho Corporate Bank, Ltd. May 2010 Joined the Company as Officer Jul 2010 General Manager, General Affairs and Public Relations Department Apr 2011 General Manager, Corporate Planning Office and General Affairs Department Jun 2011 Director; General Manager, Corporate Planning Office and General Affairs Department Jun 2012 Managing Director; General Manager, Corporate Planning Office and General Affairs Department Apr 2014 Managing Director; General Manager, Corporate Planning Office Oct 2017 Managing Director; General Manager, Corporate Planning Office and Accounting Department Apr 2018 Managing Director; General Manager, Accounting Department Jun 2018 Managing Director; General Manager, Administration Division Jun 2019 Senior Managing Director; General Manager, Administration Division Apr 2022 Representative Director, President Apr 2026 Director, Chairman of the Board (current)
1958-11-19
Hiroyoshi KASAI
Director
Apr 1994 Joined the Company Jun 2007 Head, Pharmacology and Safety Research Laboratory, Sagami Research Institute Apr 2012 General Manager, Pharmaceutical Development Department Jan 2014 General Manager, Pharmaceutical Development Division Apr 2016 Deputy Director, Sagami Research Institute Jul 2016 Deputy Director, Sagami Research Institute (Officer) Oct 2016 General Manager, Pharmaceutical Development Business Division, Development Division (Officer) Apr 2017 General Manager, Pharmaceutical Development Division (Officer) Jun 2017 Executive Officer; General Manager, Pharmaceutical Development Division Aug 2019 Executive Officer; General Manager, Pharmaceutical Development Headquarters Jun 2022 Director; General Manager, Pharmaceutical Development Headquarters Apr 2023 Director; General Manager, Pharmaceutical Development Headquarters; Head, Information Provision Activities Supervision Office Jun 2023 Director; General Manager, Pharmaceutical Development Headquarters (current)
1968-04-14
Makoto TANIGUCHI
Director
Apr 1992 Joined the Company Jul 2005 Manager, General Affairs Section, Sagami Oi Plant May 2006 Manager, Production Planning Section, Production Planning Department Sep 2009 Deputy General Manager, Production Planning Department Apr 2011 General Manager, Production Planning Department Feb 2012 General Manager, Production Department, Sagami Oi Plant Oct 2016 Plant Manager, Sagami Oi Plant Apr 2021 Executive Officer; General Manager, Production Headquarters Jun 2024 Director; General Manager, Production Headquarters (current)
1967-05-08
Haruhisa HIRATA
Director, Full-time Audit and Supervisory Committee Member
Apr 1979 Joined the Company Apr 1996 Head, Fermentation Laboratory Jun 2001 Head, Fermentation Laboratory and Head, Healthcare Laboratory Apr 2003 Deputy Director, Sagami Research Institute Jun 2007 Director, Sagami Research Institute Jun 2009 Director; Director, Sagami Research Institute Jan 2014 Director; General Manager, Regulatory Affairs and Quality Assurance Department Jun 2017 Director, Full-time Audit and Supervisory Committee Member (current)
1956-10-20
Katsuyoshi EJIMA
Director, Audit and Supervisory Committee Member
Apr 1977 Joined Dai-Ichi Kangyo Bank, Ltd. (now Mizuho Financial Group, Inc.) Apr 2004 Executive Officer; General Manager, Credit Planning Department, Mizuho Financial Group, Inc. Mar 2006 Managing Executive Officer; Group Head, Compliance Group and Group Head, Examination Group, Mizuho Corporate Bank, Ltd. Apr 2008 Managing Executive Officer, in charge of Examination Division, Mizuho Bank, Ltd. Jun 2009 President and Director, Mizuho Investors Securities Co., Ltd. Jan 2013 Director, Deputy President and Deputy President Executive Officer, Mizuho Securities Co., Ltd. Apr 2014 Senior Advisor, Mizuho Securities Co., Ltd. Jan 2016 Outside Director, Nihon House Holdings, Inc. (current) Jun 2017 Outside Corporate Auditor, the Company Director, Audit and Supervisory Committee Member, the Company (current) Jun 2020 Advisor, Nihon Tochi Tatemono Co., Ltd.
1953-12-29
Ikuro KUWABARA
Director, Audit and Supervisory Committee Member
Apr 1987 Registered as attorney-at-law (Tokyo Bar Association); joined Saito Kazuyoshi Law Office Jun 1993 Joined Terai Kazuhiro Law Office Apr 2006 Auditor (part-time), Tokyo Bar Association, FY2006 Jan 2010 Opened Kuwabara Law Office (now Kuwabara Ikeda Law Office) (current) Aug 2010 Auditor (part-time), Tokyo Metropolitan Bar Association National Health Insurance Association (current) Jun 2023 Director, Audit and Supervisory Committee Member, the Company (current)
1956-08-14
Kana HIKAWA
Director, Audit and Supervisory Committee Member
Oct 1999 Joined Chuo Audit Corporation Apr 2004 Registered as Certified Public Accountant Jul 2007 Joined Shin Nihon & Co. (now EY Shinnihon LLC) Apr 2017 Opened Hikawa Certified Public Accountant Office (current) Jul 2022 Auditor (part-time), Postal Savings and Postal Life Insurance Management and Post Office Network Support Organization (Independent Administrative Institution) (current) Jun 2024 Director, Audit and Supervisory Committee Member, the Company (current) Apr 2025 Outside Director, Audit and Supervisory Committee Member, Vestella Co., Ltd. (current)
1976-02-18
Large Shareholding Reports
Asset Value Investors Limited
2026-08-27
10.60%→11.64%
Asset Value Investors Limited
2026-01-09
9.58%→10.60%
Asset Value Investors Limited
2025-05-29
8.54%→9.58%
Asset Value Investors Limited
2025-04-01
7.45%→8.54%
Asset Value Investors Limited
2025-03-07
6.14%→7.45%
Asset Value Investors Limited
2025-02-27
6.14%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-27
Large Shareholding Report
TDnet
2026-08-05
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-18
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-04
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2026-01-09
Large Shareholding Report
EDINET
2025-11-13
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnetAmended
2025-10-31
Q1 Earnings Flash
FY ending Mar 2026
TDnet
2025-08-05
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-20
Annual Securities Report
Period: Apr 2024 – Mar 2025
EDINET
2025-05-29
Large Shareholding Report
EDINET
2025-04-01
Large Shareholding Report
EDINET
2025-03-07
Large Shareholding Report
EDINET
2025-02-27
Large Shareholding Report
TDnet
2025-02-05
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-13
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-02
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-28
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-28
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-14
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-06-24
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-06
Quarterly Securities Report
EDINET
2021-06-25
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →